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tastasis, it would be probably necessary to perform a randomised study 
including at least more than 1,000 patients. From several trial projects, 
some in Europe, only the RTOG-Intergroup US randomized trial has 
been launched and is including high risk NSCLC patients. The planned 
recruitment is above 1,000 patients and might answer the question of a 
potential effect on overall survival.
In conclusion, the controversy on the role of PCI on overall survival in 
high-risk NSCLC patients will persist in the absence of large ran-
domised studies addressing the issue. The difﬁculties to launch trials 
on this important question, which does not receive industrial ﬁnancing 
supports, are a matter of major concern. However, previous success-
ful experience of PCI in patients with SCLC certainly should encour-
age clinicians worldwide to include patients in these new randomised 
trials evaluating a potential worthwhile treatment for locally advanced 
NSCLC disease. 
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Central nervous system (CNS) failure in patients with locally advanced 
non-small cell lung cancer (LA-NSCLC) is a common and debilitating 
problem. The incidence is between 13 and 54 %.1-15,27,41 (Table 1) 
Review of RTOG data and other combined modality series have shown 
that chemotherapy signiﬁcantly decreases extra-cranial failures but 
does not decrease the risk of CNS failures. As survival lengthens the 
risk of CNS metastases increases.17-19 Studies reporting the highest 
incidence of CNS metastases include patients treated aggressively with 
multimodality therapy who have a relatively long median survival. 
(Table 1) As treatment improves for NSCLC and survival lengthens 
CNS failures will increase. 
Table 1:  Incidence of CNS metastases
CNS Metastases Median 
Survival 
(Months)
Study Stage Overall 1st Failure Site
Choi30 T1-3pN2 NA 30% 25
Stuschke3 T1-4pN2 54% 30% 20
Albain2 pN2-3 or T4 21% 15% 15
Andre12 cN2 22% 15% NA
Law10 IIIa-b or IV 31% 
(53% complete 
resection)
16.3% 
(28% complete 
resection)
20
Ceresoli11 IIb,IIIa-b NA 22% 21
Gaspar21 IIIa-b 17% 13% NA
Carolan14 III 35% 18% NA
Mamon15 IIIa 40% 34% 21
Chen41 III (preop 
therapy pCR)
55% 43% 43
There is not a standard of care for addressing CNS micro-metastases 
after successful therapy for LA-NSCLC. Most clinicians will perform 
routine physical examination with imaging of the CNS only upon 
development of signs or symptoms of CNS failure. The National 
Comprehensive Cancer Network (NCCN) guidelines for follow up of 
lung cancer include physical exam, chest x-ray, and thoracic CT scans 
at regularly deﬁned intervals. CT or MRI screening for CNS metastases 
is not included. While some investigators have evaluated and endorse 
routine neuropsychological assessment and CT or MRI screening 
for early detection of brain metastases,10,16,41 others have included 
prophylactic cranial irradiation (PCI) as part of multimodality therapy 
regimens2-4,8,22 or have suggested the need for further investigation 
of PCI.3,9,12-15,17,20 
Prospective and retrospective trials have shown that prophylactic 
cranial irradiation decreases the incidence or delays the onset of CNS 
failures in LA-NSCLC (Tables 2&3).2-7,9,22,23 Studies have not been 
powered to show a survival advantage nor have they evaluated the 
potential improvement in quality of life (QOL) or neurologic function 
by decreasing or delaying CNS metastases.
Neuropsychological complication rates of PCI in published data for 
small cell lung cancer (SCLC) and NSCLC are acceptable but data are 
limited .3,24,25 It is not known whether the beneﬁts of PCI outweigh 
the risks. Approximately 50 % of carefully selected patients with 
NSCLC treated with PCI will be treated unnecessarily. Of those treated, 
up to 13% will still have CNS failures. Early detection of asymptomatic 
CNS metastases followed by intervention with aggressive therapy may 
improve quality of life and survival without the potential risks of PCI. 
Brain metastases are more likely to be amenable to aggressive therapy 
with radiosurgery or surgical resection if disease is detected early, when 
tumor burden is low.
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Table 2:  Randomized Studies
CNS Failures
Overall 
Survival
Median 
Survival 
(Months)
Study Dose of PCI Primary TX NO PCI PCI
Cox5 (VALG) 20 Gy 
(2Gyx10)
RT only (all 
NSCLC)
13% 
(16/145)
6%  
(7/136)
NA NA
Russell6 (RTOG) 30 Gy 
(3Gyx10)
RT only (non-
squam)
19%  
(18/94)
9%  
(8/93)
13%  
(2 years)
8
Umsawasdi7 30 Gy (3 
Gyx10)
ChT/RT or 
ChT/RT/S 
(all NSCLC)
27%  
(14/51)
4% 
 (2/46)
NA NA
Table 3: Non-randomized Studies
CNS Failures
Overall 
Survival
Median 
Survival 
(Months)
Study Dose Of PCI Primary TX No PCI PCI
Albain2 (SWOG) 36 Gy 
(2Gyx18)
Trimodality 
(all NSCLC)
16% 
(16/100)
8% (2/26) 37% (2 yrs) 
27% (3 yrs)
15
Strauss4 (CALGB) 30 Gy 
(2Gyx15)
Trimodality 
(non-squam)
12%  
(5/41)
0 (0/13) 58%  
(1 year)
15.5
Stuschke3 30 Gy 
(2Gyx15)
Trimodality 
(all NSCLC)
54%  
(15/28)
13% (6/47) 
p < 0.0001) 
31%  
(3 years)
20
Skarin et al, 
1989 8
NA Trimodality 
(all NSCLC)
26%  
(7/27)
14%  
(1/7)
31%  
(3-5 years)
32
Yokoi et al evaluated the potential beneﬁts of MRI and CT to detect 
brain metastases in patients with stage I-IIIB non-small cell lung cancer 
treated surgically. Disease was detected prior to development of neuro-
logic symptoms in 76% of patients diagnosed with CNS metastases.33 
Median survival for patients with asymptomatic CNS metastases was 
25 months while overall median survival was 10 months. 
Survival favors patients with good prognostic factors and solitary le-
sions amenable to surgery26,43,44 or radiosurgery28,45 with median 
survival between 10 and 16 months. Long term survival and possible 
cure has been reported in select cases of lung cancer patients treated 
aggressively for metastatic disease to the brain.34-37 Carolan et al re-
ported median survival of 26.3 months with surgical resection and brain 
irradiation for brain metastases detected in patients after combined 
modality therapy for stage IIIA/B NSCLC.14 Overall 5 year survival 
for resected synchronous solitary brain metastases is approximately 
20%.34-37 Overall 5 year survival for brain failures after primary 
therapy is as high as 38% for favorable patients treated aggressively to 
the brain.33 
Traditionally, radiation therapy studies for CNS metastases have 
included patients with varying primary disease sites, levels of perfor-
mance status, and extent of extracranial disease. Median survival in 
these reports is only 3- 6 months.29-31 Recursive partitioning analysis 
of RTOG studies identiﬁed three prognostic groups.21 RPA Class I 
patients have KPS > 70, age < 65 years, control primary tumor, and no 
extracranial metastases. Class III patients include all patient with KPS 
<70. Class II patients include all others. Median survival for Class I-III 
is 7.1, 4.2 and 3.3 months. Other studies have conﬁrmed the value of 
RPA-derived prognostic classes.46,47
Unfortunately, patients with favorable prognostic factors represent a 
small percentage of all patients with brain failures. Twenty percent of 
patients were RPA class I, 64% class II, and 15% class III in RTOG 
studies treating brain metastases.21 Nieder et al retrospectively re-
viewed 532 consecutive patients at a single institution treated for CNS 
metastases and only 3% were RPA class I.46 
Not only do the majority of patients fall into the less favorable prog-
nostic groups, but also, the majority of patients with CNS metastases 
have multiple lesions. The incidence of solitary metastases is only18-
45%.33,41,42 Radiation in patients with multiple lesions improves or 
stabilizes neurologic function and decreases steroid use in patients who 
respond to therapy but survival is poor.38-40 These patients are not 
surgical candidates and do not derive a survival advantage to stereotac-
tic radiosurgery45 or other aggressive therapy. 
A small percentage of patients with LA-NSCLC with control of 
extra-cranial disease may develop solitary CNS metastases and have a 
small chance for cure with surgery or stereotactic radiosurgery with or 
without whole brain irradiation (WBI). The chance for 5 year survival 
under the best circumstances is 38%.33 If treated with PCI about 50% 
of these patients may have been spared the long term consequences 
of brain metastases and treatment. Patients with multiple lesions have 
no chance of curative therapy, only a small beneﬁt in terms of neuro-
logic improvement, and will likely die a neurologic death. Chen et al 
reported that 88% of patients with brain as ﬁrst site of failure and 70% 
of all patients with CNS failures died as a result of brain metastases. 
Prevention of CNS failures will improve survival in patients with con-
trol of extra-cranial disease otherwise destined for solitary or multifo-
cal CNS failures. PCI may delay or prevent CNS failure and prolong 
neurologic symptom free interval, thus improving overall quality of life 
in patients that fail outside of the CNS and are otherwise not cured of 
their disease.
The consequences of CNS failure are severe. Prophylactic treatment 
is effective in decreasing the incidence with limited toxicity. For a 
small percentage of patients prevention may result in cure and in others 
prevention or delay of CNS metastases will improve quality of life. 
Whether the beneﬁts of PCI outweigh the risks can only be determined 
by a carefully designed prospective study randomizing patients to PCI 
or observation with neuropsychological evaluation in both groups. 
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The management of IIIA NSCLC challenges the surgeon and the mul-
tidisciplinary team given the heterogeneity of the local disease and the 
variable incidence of regional and systemic metastasis. Invasive staging 
with pathology examination of lymph node or other tissues further 
describes the clinical extent of the disease to reﬁne treatment decisions. 
Patients with involved N2 nodes should be preferentially considered for 
entry into a prospective clinical trial, or therapy with local and systemic 
treatment(s). 
Induction therapy has been undertaken to improve survival in patients 
with clinical stage IIIA (N2) disease. Recent multi-institutional studies 
[1] have suggested a beneﬁt from induction chemotherapy. Adjuvant 
therapy has shown survival beneﬁt in various prospective randomized 
clinical trials and meta-analyses. [2, 3] 
The North American Intergroup 0139 phase III study of concurrent 
chemotherapy and radiotherapy (CT/RT) vs. CT/RT followed by 
surgical resection (S) for stage IIIA (pN2) NSCLC was designed to 
evaluate the role of resection after chemotherapy and radiation therapy. 
Pneumonectomy accounted for 14/15 postoperative deaths and may 
have compromised overall survival. The study showed that 1) progres-
sion free survival was better with resection after chemoradiotherapy, 2) 
a non-signiﬁcant survival advantage was shown with CT/RT+S; 3) pN0 
status was associated with prolonged survival, and 4) although S may 
be considered in ﬁt patients, the results with pneumonectomy are no 
different than with CT/RT alone.[4] 
The down-staging identiﬁed with induction therapy is important in 
identifying patients with improved chances for survival. Patient with 
persistent N2 disease after induction therapy have poorer survival and 
should not typically be considered as operative candidates. SWOG 
8805 (phase II) evaluated induction chemoradiotherapy followed by 
resection for patients with cStage IIIA and cStage IIIB. This strategy 
provided a pathological complete response in 22%; overall survival 
(3-years) was 27%. Patients with no residual mediastinal lymph node 
metastasis had a median survival of 30 months compared to 10 months 
with residual disease (p=0.0005). [5] Another study identiﬁed a com-
plete response rate of 28% following induction chemoradiotherapy. 5 
year survival was 35.8% compared to 9% with residual nodal disease 
(p=0.023).[6] Alternatives to the initial mediastinal staging include 
esophageal ultrasound (EUS) and transbronchial ultrasound (TBUS) 
Resection should be avoided after induction therapy in patients who 
have biopsy-proven residual tumor in the mediastinal nodes. The ben-
eﬁt of resection over and above that achieved with combined chemo-
therapy and radiation therapy is small and may carry signiﬁcant opera-
tive and perioperative risk. If only a lobectomy would be performed, 5 
year survival may reach 40% following induction CT/RT. 
Selection of optimal treatment for patient with NSCLC requires excel-
lent pretreatment staging and clinical evaluation with discussion of 
all therapeutic possibilities by the integrated multidisciplinary care 
team: thoracic surgeon, pulmonologist, radiation oncologist, medical 
oncologist, and allied specialties. The clinician balances the risks from 
local and systemic therapies of NSCLC (local disease control, pain 
relief, improved survival) and the beneﬁts of improvement in survival 
and quality of life, based upon the individual patientís characteristics, 
co-morbidities, clinical stage and perioperative evaluation. Multidisci-
plinary evaluation, consistency of clinical evaluation and therapeutic 
approach, application of proven intraoperative and perioperative tech-
niques, completeness of resection, and adequacy of mediastinal lymph 
node dissection, etc., all beneﬁt the patient by optimizing local control 
and subsequent therapeutic decisions. 
Table 1. Primary Therapy Considerations for IIIA Non-Small Cell Lung 
Carcinoma 
Note: All patients should be considered for participation into therapeu-
tic clinical trials.
• Accurate clinical staging with FDG-PET is essential for optimizing 
therapeutic recommendations.[7]
• If clinical staging conﬁrms (histologically) metastasis to N2 lymph 
nodes, chemoradiotherapy is effective.[8]. Following R0 resection, 
patients with metastasis to N2 lymph nodes should be considered for 
adjuvant chemotherapy to enhance survival.[2, 3, 9]
• The role of preoperative chemotherapy and radiation therapy for 
limited stage IIIa is unclear.[4] 
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